Brawn Biotech Ltd has announced that its board of directors will meet on Friday, May 29, 2026. The primary agenda for the meeting is to consider and approve the audited financial results of the company for the quarter and financial year ended March 31, 2026.

Board Meeting Details

The meeting is being convened pursuant to Regulation 29(1)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The board will review the company's performance for the fourth quarter of the fiscal year 2026 and the full fiscal year.

Trading Window Closure

In accordance with the company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, the trading window for dealing in the securities of the company will remain closed. This closure period is effective immediately and will continue until May 31, 2026. The window is scheduled to reopen on June 1, 2026.

The intimation regarding the trading window closure was initially communicated via a letter dated March 30, 2026. This measure ensures compliance with regulatory standards regarding insider trading during the period surrounding financial result announcements.

Brawn biotech Limited has officially communicated to BSE Limited that it does not qualify as a Large Corporate under the Securities and Exchange Board of India's regulatory framework. The declaration was submitted on April 13, 2026, by Company Secretary and Compliance Officer Priyanka Sharma.

Regulatory Compliance Declaration

The company's declaration references two key SEBI circulars that govern fund raising by Large Corporates through debt securities. These include SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018, and SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 dated October 19, 2023. Under these regulations, companies meeting specific criteria must comply with enhanced disclosure requirements and borrowing frameworks.

Company Financial Position

The formal disclosure reveals Brawn Biotech Limited's current financial standing regarding borrowings and credit ratings:

Large Corporate Framework Criteria

The SEBI Large Corporate framework establishes specific thresholds and criteria that determine whether a company falls under enhanced regulatory oversight for debt securities. Companies that qualify as Large Corporates face additional compliance requirements, including mandatory borrowing through debt securities for incremental funding needs above specified limits.

Corporate Information

Brawn Biotech Limited operates with CIN L74899DL1985PLC022468 and maintains its registered office at C-64, Lajpat Nagar-1, First Floor, New Delhi-110024. The company's manufacturing facility is located at Plot No.44, Pace City-1, Sector 37, Near Hero Honda Chowk, Gurugram, Haryana. The declaration was digitally signed and submitted with the company's official seal, ensuring proper authentication of the regulatory communication.